Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects.

1. The effects of a single oral dose of enalapril 10 mg on serum ACE activity and blood pressure in relation to the ACE genotype were studied in 27 healthy men, n = 9 each of genotype DD, ID and II, in a parallel group study design. 2. Before treatment serum ACE activity differed significantly between the genotypes, with serum ACE activity 56% higher in DD than II subjects, and the genotype explaining 40% of between-subject variance in serum ACE activity. 3. After oral enalapril 10 mg the absolute fall in serum ACE activity was significantly larger in DD than II subjects at 2, 4, and 6 h (by 9.0 (95% CI 0.7-17.2), 10.7 (3.8-17.6), and 9.7 (2.8-16.6) nmol ml-1 min-1 respectively), but not at 24 h (fall in II > DD by 1.1 (-8.9 to 6.7) nmol ml-1 min-1). 4. Serum ACE activity remained significantly related to the ACE genotype at each time-point after enalapril, with the genotype explaining 22-46% of between-subject variance in serum ACE. 5. Falls in mean arterial pressure in response to enalapril were not significantly related to the ACE genotype, with the average fall over 6 h in DD > II genotype by 0.7 mm Hg (95% CI -5.5 to 4.1). 6. Blood pressure responses to enalapril did not correlate significantly with the initial serum ACE, or the absolute or percent reductions in serum ACE activity after enalapril.(ABSTRACT TRUNCATED AT 250 WORDS)

[1]  J. D. Swales,et al.  Molecular biology of the renin cascade in hypertension Report of a Meeting of Physicians and Scientists, University of Leicester , 1994, The Lancet.

[2]  E. Espiner MYOCARDIAL INFARCTION Kindred hearts and coronaries , 1993, The Lancet.

[3]  E. Espiner Kindred hearts and coronaries. , 1993, Lancet.

[4]  T. Kurtz The ACE of hearts , 1992, Nature.

[5]  Philippe Amouyel,et al.  Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction , 1992, Nature.

[6]  B. Morris,et al.  Association of a polymorphism of the angiotensin I-converting enzyme gene with essential hypertension. , 1992, Biochemical and biophysical research communications.

[7]  S. Hunt,et al.  Absence of linkage between the angiotensin converting enzyme locus and human essential hypertension , 1992, Nature Genetics.

[8]  F. Soubrier,et al.  PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). , 1992, Nucleic acids research.

[9]  P Corvol,et al.  An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. , 1990, The Journal of clinical investigation.

[10]  R. Heel,et al.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. , 1986, Drugs.

[11]  C. Johnston,et al.  Relationship of antihypertensive effect of enalapril to serum MK-422 levels and angiotensin converting enzyme inhibition. , 1983, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[12]  A T Barker,et al.  Clinical evaluation of Dinamap 845 automated blood pressure recorder. , 1980, British heart journal.

[13]  E. Silverstein,et al.  A sensitive fluorimetric assay for serum angiotensin-converting enzyme. , 1976, American journal of clinical pathology.